Canaccord Genuity Maintains Buy on Intellia Therapeutics, Raises Price Target to $73
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Intellia Therapeutics (NTLA) and raises the price target from $72 to $73.
February 23, 2024 | 2:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Intellia Therapeutics and raises the price target from $72 to $73.
The increase in price target by Canaccord Genuity, a reputable financial services firm, suggests a positive outlook on Intellia Therapeutics' stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100